Skip to main content
. 2021 Feb 27;2021:6683098. doi: 10.1155/2021/6683098

Table 1.

COVID-19 patients' characteristics at the time of administration.

Characteristic Total (n = 172) (%) Hydroxychloroquine (n = 29) (16.9%) Hydroxychloroquine and azithromycin (n = 143) (83.1%) p value
Age, mean ± SD (year) 59.2 ± 15.4 59.1 ± 17.9 59.8 ± 14.8 0.577
Female 85 (49.4) 16 (55.1) 69 (48.2) 0.497
Intensive care at time of testing 17 (9.8) 3 (10.3) 14 (9.7) 0.927
Tisdale score at treatment initiation, mean ± SD 8 ± 2.1 5.8 ± 2.3 8.4 ± 1.8 <0.001
Acute heart failure 28 (16.2) 6 (20.6) 22 (15.3) 0.480
Maximum temperature at the time of administration, mean ± SD (°C) 37.1 ± 0.5 37.1 ± 0.4 37.2 ± 0.5 0.192
Baseline laboratory values, mean ± SD
 Serum potassium, mean ± SD (mEq/L) 4.2 ± 0.3 4.3 ± 0.3 4.1 ± 0.3 0.062
 Serum creatinine, mean ± SD (mg/dL) 1.2 ± 1.1 1.1 ± 0.3 1.2 ± 1.2 0.810
 White blood cell count, mean ± SD (cells/μL) 7140.1 ± 3501.4 7848.6 ± 4880.4 6995.2 ± 3128.1 0.627
 Absolute lymphocyte count, mean ± SD (count/μL) 22.78 ± 9.6 23.1 ± 12.3 22.71 ± 9.1 0.325
 C-reactive protein, mean ± SD (mg/dL) 8.8 ± 5.9 9.6 ± 7.4 8.6 ± 5.6 0.708
 Creatine phosphokinase, mean ± SD (IU/L) 232.4 ± 395.5 146.4 ± 55.9 272.5 ± 473.7 0.940
 Lactate dehydrogenase, mean ± SD (IU/L) 642.9 ± 358.7 507.2 ± 219.3 679.1 ± 380.3 0.003
Preexisting conditions
 Hypertension 53 (30.8) 10 (34.4) 43 (30.1) 0.639
 Congestive heart failure 48 (27.9) 4 (13.7) 44 (30.7) 0.063
 Coronary artery disease 11 (6.3) 0 (0) 11 (7.6) 0.123
 Atrial fibrillation 2 (1.2) 1 (3.4) 1 (0.7) 0.208
 Diabetes mellitus 60 (34.8) 7 (24.1) 53 (37.1) 0.183
 Chronic obstructive pulmonary disease 4 (2.3) 0 (0) 4 (2.7) 0.362
 Malignancy 7 (4.1) 2 (6.8) 5 (3.4) 0.398
 Chronic kidney disease 10 (5.8) 1 (3.4) 9 (6.2) 0.550
Medications
 Loop diuretics 41 (23.8) 8 (27.5) 33 (23.1) 0.603

Abbreviations: SD: standard deviation.